ArticleMethods in molecular biology (Clifton, N.J.)2025
Quantification of β-Lactamase Inhibition Using a Luminescent Whole-Cell Biosensor.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical utility of the β-lactam antibiotics is threatened by resistant bacterial pathogens that produce β-lactamases. These enzymes hydrolytically degrade β-lactams, rendering them ineffective. Although several β-lactamase inhibitors have been approved for clinical use, currently used inhibitors only target a subset of the clinically relevant β-lactamases. Additionally, β-lactamase variants that exhibit reduced susceptibility to these inhibitors are increasing in prevalence. Thus, drug discovery efforts must continue to identify and develop novel β-lactamase inhibitors. Herein, we describe a luminescent biosensor, based on the β-lactam-inducible AmpR regulon, which can be used to quantify β-lactamase inhibition in bacterial cells. This approach does not require the use of expensive substrates and can account for factors such as outer membrane permeability, prioritizing the discovery of inhibitors that are effective against bacterial cells.
Indexed as
Identifiers
40498315What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.